Vaccine trials to cure Ebo
la are to begin in Oxford. The first one of the 60 healthy volunteers will have injection of the vaccine. The vaccine has a minute amount of Ebola virus' genetic material. It will be unable to cause the disease.
In normal routine years are spent in experiments for a new vaccine to be approved for use. But quite unusually in this case the experimental vaccine is being tracked at an astonishing fast pace due to the emergency situation.
If these trials become successful, the vaccine will be used to immunize the health workers who are serving in the affected areas at the end of the year.
Around 10,000 doses of the vaccine should be made available for the purpose. GlaxoSmithKline and US National Institute of Health are working on the project.
The UK Department for international Development and Wellcome Trust, Medical Council are funding the trials. The focus is on two things; to produce effective immune response and minimum side effects.
